ICR/LinkedIn
May 24, 2025, 17:04
Kathy Chung Ying Chan Has Been Appointed as Group Leader of Theranostics at ICR
The Institute of Cancer Research shared a post on LinkedIn:
“Radiopharmaceuticals – a groundbreaking approach combining diagnostic imaging with targeted radiotherapy – is emerging as a powerful tool in personalised cancer treatment.
Dr Kathy Chung Ying Chan, newly appointed Group Leader of the Experimental and Translational Theranostics Group at the ICR, is developing novel radiopharmaceuticals that both detect and treat tumours with high precision. Her lead compound, KK02, has shown strong potential in preclinical models and may one day help treat aggressive cancers such as prostate, pancreatic, and breast cancer.
Early results demonstrate effective tumour targeting with minimal side effects – an essential step towards safer, more effective therapies. Dr Chan’s work also explores the potential of combining radiopharmaceuticals with immunotherapy to improve outcomes for hard-to-treat cancers. Read more about Dr Chan’s research, and its implications for the future of oncology.”
More posts featuring ICR.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 24, 2025, 17:04
May 24, 2025, 16:38
May 24, 2025, 16:24
May 24, 2025, 16:24
May 24, 2025, 15:58
May 24, 2025, 15:30
May 24, 2025, 14:53